Evidence map›Paper›PMID 28039162›Full record

ArticleCancer immunology research2017

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.

Theodore S Nowicki, Ryan Akiyama, Rong Rong Huang, I Peter Shintaku, Xiaoyan Wang, Paul C Tumeh, Arun Singh, Bartosz Chmielowski, Christopher Denny, Noah Federman and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 69 citations in OpenAlex.

  1. Trial
  2. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Targeting cancer testis antigens in synovial sarcoma.Journal for immunotherapy of cancer · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Theodore S NowickiDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
Ryan AkiyamaDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
Rong Rong HuangDepartment of Pathology, University of California Los Angeles, Los Angeles, California.
I Peter ShintakuDepartment of Pathology, University of California Los Angeles, Los Angeles, California.
Xiaoyan WangDepartment of General Internal Medicine, University of California Los Angeles, Los Angeles, California.
Paul C TumehDivision of Dermatology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Arun SinghDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
Bartosz ChmielowskiDivision of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California.
Christopher DennyDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
Noah FedermanDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
Antoni RibasDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
NCI NIH HHS P01 CA168585NCI NIH HHS R35 CA197633
6 · The paper itself

Abstract

Tumors expressing programmed death ligand 1 (PD-L1) interact with the corresponding negative-signal generating immune receptor on the surface of CD8 T cells, PD-1, thereby suppressing antitumor activity. Therapeutics blocking this interaction have shown promise in various cancers by restoring functional antitumor T-cell activity. We explored the degree of PD-L1, PD-1, and CD8 expression in a retrospective analysis of 29 clinical synovial sarcoma samples. Quantitative immunohistochemistry and multiplex immunofluorescence were used to determine relative quantification of CD8

Indexed as

B7-H1 AntigenCD8-Positive T-LymphocytesGene ExpressionHumansImmunohistochemistryKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingNeoplasm MetastasisNeoplasm StagingProgrammed Cell Death 1 ReceptorRetrospective StudiesSarcoma, SynovialB7-H1 AntigenProgrammed Cell Death 1 Receptor

Identifiers

PMID28039162
PMCPMC5290092
OpenAlexW2563528514

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.